Cliquez pour voir la ligne de temps
Ligne de temps
Projets
Anciennes Équipes
Publications
Télécharger-
2024A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model., J Virol 2024 Apr; (): e0169323.
-
2023Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings, Diagn Microbiol Infect Dis . 2023 Apr;105(4):115903. .
-
2022Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study., EBioMedicine 2022 Jan; 75(): 103810.
-
2021Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance., Nat Commun 2021 05; 12(1): 3025.
-
2021High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris., Eur J Immunol 2021 01; 51(1): 180-190.
-
2020Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models., Cell Host Microbe 2021 Feb 10;29(2):236-249: .
-
2020A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations, Science Translational Medicine, 2020, 12 (559), pp.eabc3103. ⟨10.1126/scitranslmed.abc3103⟩.